Amazon S3 on MSN

Revolutionary AI identifies cancer risk with high precision

Researchers may have made a significant advancement in forecasting one of the most perilous aspects of cancer — metastasis. In this video, we delve into an innovative AI model crafted by scholars at ...
CURE

Tazverik Withdrawn From All Markets Over Safety Concerns

Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...
Targeted Oncology

Sequencing Therapy for HER2-Positive Metastatic Breast Cancer: Emerging Strategies

PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...
Amazon S3 on MSN

Breakthrough AI spots cancer risk with high accuracy

Scientists may have just taken a huge step toward predicting one of cancer’s most dangerous behaviors — metastasis. In this video, we explore a groundbreaking artificial intelligence model developed ...
The News International

Scientists build AI tool to track tumor behaviour

Scientists at the University of Geneva have created a new AI system that can predict the chances of cancer spreading to other parts of the body. The new AI system, named MangroveGS, studies ...
Kauppalehti

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on ...